QIAGEN Reports Preliminary Q1 2026 Results and Updates Outlook
QIAGEN N.V. announced its preliminary results for the first quarter of 2026, achieving its adjusted diluted earnings per share (EPS) outlook. Despite mixed sales trends, with lower sales from QuantiFERON and cautious demand in the U.S. Life Sciences sector, the company reported preliminary net sales of $492 million, reflecting a 2% increase.
VENLO, the Netherlands–(BUSINESS WIRE)—- $QGEN #QIAGEN–QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced preliminary results for the first quarter of 2026, continuing to deliver strong profitability as adjusted diluted earnings per share (EPS) achieved the outlook. Sales trends were mixed, as lower QuantiFERON sales and cautious U.S. Life Sciences customer demand offset solid growth in other areas of the portfolio. For Q1 2026, preliminary net sales were $492 million, up 2% on a reporte